NCT02673749View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

377

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Lactose Intolerance
Interventions
DRUG

RP-G28

Study drug taken orally

OTHER

Placebo

Placebo taken orally

Trial Locations (1)

08540

Covance, Inc., Princeton

All Listed Sponsors
lead

Ritter Pharmaceuticals, Inc.

INDUSTRY

NCT02673749 - Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance | Biotech Hunter | Biotech Hunter